BioCentury
ARTICLE | Clinical News

Blueprint reports updated Phase I data for BLU-285 in GIST

June 15, 2017 8:44 PM UTC

Blueprint Medicines Corp. (NASDAQ:BPMC) reported updated data from an open-label, international Phase I trial evaluating once-daily 30-600 mg oral BLU-285 to treat unresectable gastrointestinal tumors (GIST) and other relapsed or refractory solid tumors. In 25 evaluable patients with platelet derived growth factor receptor A (PDGFRA; PDGFR2; CD140A)-driven GIST, BLU-285 led to an overall response rate (ORR) of 60% as measured by RECIST criteria, including 15 partial responses, plus 10 cases of stable disease. Median progression-free survival (PFS) was not reached and the estimated 9-month PFS rate was 87%.

In 25 evaluable patients with stem cell factor (SCF) receptor tyrosine kinase (c-Kit; KIT; CD117)-driven GIST, BLU-285 led to an ORR of 8%, including 2 partial responses, plus 12 cases of stable disease. Median PFS was 9.3 months in patients who received BLU-285 at doses of 300 mg or higher. The maximum tolerated dose (MTD) is once-daily 400 mg BLU-285. Data were presented at the American Society of Clinical Oncology meeting in Chicago...